Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi

International Journal of Antimicrobial Agents

Volumn 40, Issue 1, 2012, Pages 61-71

  Veiga Santos, Phercyles ^a   Barrias, Emile S ^a,c   Santos, Júlio F C ^a   De Barros Moreira, Thiago Luiz ^a   De Carvalho, Tecia Maria Ulisses ^a   Urbina, Julio A ^b   De Souza, Wanderley ^a,c  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^c INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

Amiodarone; Autophagy; Posaconazole; Synergism; Trypanosoma cruzi

Indexed keywords

AMIODARONE; LIPID; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3; POSACONAZOLE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL DEATH; CELL SWELLING; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; EPIMASTIGOTE; EUKARYOTIC FLAGELLUM; GOLGI COMPLEX; IC 50; IMMUNOFLUORESCENCE MICROSCOPY; KINETOPLAST; LIPID STORAGE; MEMBRANE VESICLE; MICROBIAL GROWTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TRANSMISSION ELECTRON MICROSCOPY; TRYPANOSOMA CRUZI;

AMIODARONE; ANIMALS; ANTIMALARIALS; AUTOPHAGY; CELL SURVIVAL; DRUG INTERACTIONS; INHIBITORY CONCENTRATION 50; MICE; MICROSCOPY, ELECTRON; ORGANELLES; TRIAZOLES; TRYPANOSOMA CRUZI;

EID: 84861869443     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.03.009     Document Type: Article

References (30)

1. World Health Organization. Control of Chagas disease. Second report of the WHO Expert Committee. Geneva, Switzerland: WHO; 2002. Technical Report Series No. 905.
2. Dias JCP. Elimination of Chagas disease transmission: perspectives. Mem Inst Oswaldo Cruz 2009;104(Suppl. 1):41-5.
3. Rassi Jr A, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010;375:1388-402.
4. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 2003;19:495-501. (Pubitemid 37329658)
5. Adade CM, Souto-Padrón T. Contributions of ultrastructural studies to the cell biology of trypanosmatids: targets for anti-parasitic drugs. Open Parasitol J 2010;4:178-87.
6. Veiga-Santos P, Pelizzaro-Rocha KJ, Santos AO, Ueda-Nakamura T, Dias Filho BP, Silva SO, et al. In vitro anti-trypanosomal activity of elatol isolated from red seaweed Laurencia dendroidea. Parasitology 2010;137:1661-70.
7. Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther 2009;34:301-11.
8. Buckner FS, Navabi N. Advances in Chagas disease drug development: 2009-2010. Curr Opin Infect Dis 2010;23:609-16.
9. Urbina JA, Payares G, Contreras LM, Liendo A, Sanoja C, Molina J, et al. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 1998;42:1771-7. (Pubitemid 28311577)
10. Silva DT, de Nazarth SL, de Meirelles M, Almeida D, Urbina JA, Pereira MC. Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors. Int J Antimicrob Agents 2006;27:530-7. (Pubitemid 43767077)
11. Pinazo MJ, Espinosa G, Gállego M, López-Chejade PL, Urbina JA, Gascón J. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010;82: 583-7.
12. Urbina JA. New insights in Chagas disease treatment. Drugs Fut 2010;35:409-19.
13. Benaim G, Sanders JM, Garcia-Marchán Y, Colina C, Lira R, Caldera AR, et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 2006;49:892-9. (Pubitemid 43221637)
14. Menna-Barreto RF, Salomão K, Dantas AP, Santa-Rita RM, Soares MJ, Barbosa HS, et al. Different cell death pathways induced by drugs in Trypanosoma cruzi: an ultrastructural study. Micron 2009;40:157-68.
15. Adade CM, Cons BL, Melo P, Souto-Padrón T. Effect of Crotalus viridis viridis snake venom on the ultrastructure and intracellular survival of Trypanosoma cruzi. Parasitology 2011;138:46-58.
16. Matsuo AL, Silva LS, Torrecilhas AC, Pascoalino BS, Ramos TC, Rodrigues EG, et al. In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease. Antimicrob Agents Chemother 2010;54:3318-25.
17. Nguewa PA, Fuertes MA, Valladares B, Alonso C, Pérez JM. Programmed cell death in trypanosomatids: a way to maximize their biological fitness? Trends Parasitol 2004;20:375-80. (Pubitemid 38916527)
18. Youle JR, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011;12:9-14.
19. Zingales B, Andrade SG, Briones MR, Campbell DA, Chiari E, Fernandes O, et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz 2009;104:1051-4.
20. Camargo EP. Growth and differentiation in Trypanosoma cruzi, I. Origin of metacyclic trypanosomes in liquid media. Rev Inst Med Trop Sao Paulo 1964;6:93-100.
21. Hallander HO, Dornbush K, Gezelius L, Jacobson K, Karlsson I. Synergism between aminoglycosides and cephalosporin with antipseudomonal activity: interaction index and killing curve method. Antimicrob Agents Chemother 1982;22:743-52. (Pubitemid 13210049)
22. Macedo-Silva ST, de Oliveira Silva TL, Urbina JA, de Souza W, Rodrigues JC. Antiproliferative, ultrastructural, and physiological effects of amiodarone on promastigote and amastigote forms of Leishmania amazonensis. Mol Biol Int 2011;2011:876021.
23. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt K, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66. (Pubitemid 43190980)
24. Debbas NM, du Cailar C, Bexton RS, Demaille JG, Camm AJ, Puech P. The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J 1984;51:316-20. (Pubitemid 14164695)
25. 24(25)-sterol methyl transferase on the ultrastructure of epimastigotes of Trypanosoma cruzi. Microsc Microanal 2005;11:506-15.
26. Lazardi K, Urbina JA, de Souza W. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 1990;34:2097-105. (Pubitemid 20373840)
27. Adesse D, Azzam EM, Meirelles Mde N, Urbina JA, Garzoni LR. Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro. Antimicrob Agents Chemother 2001;55:203-10.
28. Doyle PS, Chen C-K, Johnston JB, Hopkins SD, Leung SSF, Jacobson MP, et al. A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob Agents Chemother 2010;54:2480-8.
29. Lorente OS, Rodrigues JCF, Jiménez-Jiménez C, Joyce-Menekse M, Rodrigues C, Croft SL, et al. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob Agents Chemother 2004;48: 2937-50. (Pubitemid 38989159)
30. Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 2009;16:97-110.